Understanding HIV drug resistance in Kenya's new treatment era
Official title: HIV Drug Resistance in the New Antiretroviral Therapy Era in Kenya
Funded at Miriam Hospital · NIH-11009189 · Data updated 2026-11-12
This study is looking at how HIV can become resistant to new treatments in Kenya, especially in places with limited resources, to help improve care and outcomes for people living with HIV.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Miriam Hospital NIH-funded |
| Lab location | 1 site (Providence, United States) |
| Project start | September 12, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $645,900 |
| NIH project number | 1R01AI186632-01 |
| Project ID | NIH-11009189 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV in Kenya, particularly those experiencing treatment challenges or drug resistance.
✕Less likely to help
Patients who are not living with HIV or those who are not receiving antiretroviral therapy may not benefit from this research.
What this research studies
This research investigates how HIV develops resistance to new antiretroviral therapies in Kenya, particularly focusing on the challenges faced in resource-limited settings. It aims to improve treatment monitoring and drug resistance testing, which are crucial for effective HIV management. By analyzing the factors contributing to drug resistance, including the prevalence of different HIV-1 subtypes and co-infections like HIV-TB, the study seeks to enhance patient care and treatment outcomes. The research will involve collecting and analyzing data from patients to better understand the dynamics of drug resistance.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for HIV patients, reducing the incidence of drug resistance and enhancing overall health outcomes.
How similar studies have gone: Previous research has shown success in understanding HIV drug resistance dynamics in other regions, suggesting that this approach could yield valuable insights in Kenya as well.
Where this research is happening
-
Miriam Hospital
Providence, United States Active
Researchers
- Principal investigator: Kantor, Rami — Miriam Hospital
- Study coordinator: Kantor, Rami
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.